Soluble CD36 and Risk Markers of Insulin Resistance and Atherosclerosis Are Elevated in Polycystic Ovary Syndrome and Significantly Reduced During Pioglitazone Treatment
Author:
Glintborg Dorte1, Højlund Kurt1, Andersen Marianne1, Henriksen Jan Erik1, Beck-Nielsen Henning1, Handberg Aase2
Affiliation:
1. Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark 2. Clinical Biochemical Department, Aarhus University Hospital, Aarhus, Denmark
Abstract
OBJECTIVE—We investigated the relation between soluble CD36 (sCD36), risk markers of atherosclerosis and body composition, and glucose and lipid metabolism in polycystic ovary syndrome (PCOS).
RESEARCH DESIGN AND METHODS—Thirty PCOS patients were randomized to 30 mg/day pioglitazone or placebo for 16 weeks. Fourteen weight-matched healthy female subjects were included as control subjects. sCD36, oxidized LDL (oxLDL), high-sensitivity C-reactive protein (hsCRP), interleukin (IL)-6, euglycemic-hyperinsulinemic clamps, and whole-body dual-energy X-ray absorptiometry scans were performed.
RESULTS—sCD36 (2.87 relative units [0.88–9.36] vs. 1.67 relative units [0.72–3.89]), oxLDL (44.9 units/l [26.9–75.1] vs. 36.1 units/l [23.4–55.5]), and hsCRP (0.26 mg/dl [0.03–2.41] vs. 0.12 mg/dl [0.02–0.81]) were significantly increased in PCOS patients versus control subjects (geometric mean ± 2 SD). In PCOS, positive correlations were found between central fat mass and sCD36 (r = 0.43), hsCRP (r = 0.43), and IL-6 (r = 0.42) (all P < 0.05). After adjusting for fat mass, sCD36 and oxLDL correlated inversely with measures of insulin-stimulated glucose metabolism and positively with lipid oxidation during insulin stimulation in PCOS patients and control subjects (n = 44). sCD36 and oxLDL were significant independent predictors of glucose and lipid metabolism, whereas hsCRP and IL-6 showed no significant contribution. Following pioglitazone treatment, insulin sensitivity increased, whereas sCD36 (3.21 relative units [0.76–13.6] vs. 2.33 relative units [0.84–6.46]) and hsCRP decreased (P < 0.05). No significant changes were measured in body composition.
CONCLUSIONS—sCD36 and oxLDL correlated with measures of insulin sensitivity independent of central fat mass. Pioglitazone treatment reduced sCD36 while improving insulin-stimulated glucose metabolism, further supporting the association between sCD36 and insulin resistance in PCOS.
Publisher
American Diabetes Association
Subject
Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference23 articles.
1. Glintborg D, Henriksen JE, Andersen M, Hagen C, Hangaard J, Rasmussen P, Schousboe K, Hermann AP: The prevalence of endocrine diseases and abnormal glucose tolerance tests in 340 Caucasian, premenopausal women with hirsutism as primary diagnosis. Fertil Steril 82: 1570–1579, 2004 2. Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A: Polycystic ovary syndrome and risk for myocardial infarction: evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 71: 599–604, 1992 3. Orio F Jr, Palomba S, Spinelli L, Cascella T, Tauchmanova L, Zullo F, Lombardi G, Colao A: The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab 89: 3696–3701, 2004 4. Orio F, Jr, Palomba S, Cascella T, Di Biase S, Manguso F, Tauchmanova L, Nardo LG, Labella D, Savastano S, Russo T, Zullo F, Colao A, Lombardi G: The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome. J Clin Endocrinol Metab 90: 2–5, 2005 5. Nasiek M, Kos-Kudla B, Ostrowska Z, Marek B, Kudla M, Sieminska L, Kajdaniuk D, Foltyn W, Zemczak A: Acute phase proteins: C-reactive protein and fibrinogen in young women with polycystic ovary syndrome. Pathophysiology 14: 23–28, 2007
Cited by
88 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|